Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| HGH (Somatropin) | Thymosin Alpha-1 | |
|---|---|---|
| Category | Growth Factors | Growth Factors |
| Standard Dose | Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only). | Research indicates 1.6 mg administered twice weekly via subcutaneous injection. |
| Timing | Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action. | Morning administration preferred. No food timing restrictions. |
| Cycle Duration | Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong. | 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance. |
| Evidence Level | strong_human | strong_human |
Human Growth Hormone (somatropin) is a 191-amino acid single-chain polypeptide produced by anterior pituitary somatotrophs. It binds the GH receptor (GHR), activating JAK2-STAT5 signaling and MAP kinase pathways. Systemically, HGH upregulates hepatic IGF-1 production, which mediates most of its anabolic effects through IGF-1R/PI3K/Akt/mTOR-driven protein synthesis. Direct GH effects include lipolysis activation, insulin antagonism, chondrocyte/osteoblast stimulation, and enhanced collagen synthesis. Effects are divided into direct (lipolysis, insulin antagonism) and indirect (IGF-1-mediated growth and anabolism).
Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only).
Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action.
Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.
Research indicates 1.6 mg administered twice weekly via subcutaneous injection.
Morning administration preferred. No food timing restrictions.
8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →